1. Get the Diabetes Forum App for your phone - available on iOS and Android.
    Dismiss Notice
  2. Guest, we'd love to know what you think about the forum! Take the Diabetes Forum Survey 2021 »
    Dismiss Notice
  3. Diabetes Forum should not be used in an emergency and does not replace your healthcare professional relationship. Posts can be seen by the public.
    Dismiss Notice
  4. Guest, stay home, stay safe, save the NHS. Stay up to date with information about keeping yourself and people around you safe here and GOV.UK: Coronavirus (COVID-19). Think you have symptoms? NHS 111 service is available here.
    Dismiss Notice
Dismiss Notice
Find support, ask questions and share your experiences. Join the community »

US approves Farxiga to reduce heart failure hospitalisation risk for people with type 2...

Discussion in 'Diabetes News' started by DCUK NewsBot, Oct 24, 2019.

  1. DCUK NewsBot

    DCUK NewsBot · Well-Known Member

    Likes Received:
    Trophy Points:
    Dapagliflozin (Farxiga) has been approved in the US as a treatment to reduce the risk of hospitalisation for heart failure. The US Food and Drug Administration (FDA) approved this specific use of the drug for people with type 2 diabetes that have either established cardiovascular disease or a number of cardiovascular risk factors. Made by AstraZeneca, Farxiga is a sodium glucose co-transporter 2 (SGLT2) inhibitor medication. These medications help the kidneys to filter more glucose out of the blood, allowing the excess glucose to be passed out of the body via urine. In the UK, dapagliflozin is prescribed under the slightly different name of Forxiga. The decision to approve the drug comes nearly a year after results from the DECLARE-TIMI 58 trial, involving over 17,000 people, was published. The study showed significantly lower rates of hospitalisation for heart failure in people taking dapagliflozin compared with those taking a placebo. Lead researcher Dr Stephen Wiviott, from Brigham and Women's Hospital and Harvard Medical School, said: "DECLARE-TIMI 58 is a landmark trial, offering compelling evidence that dapagliflozin can reduce the risk of heart failure in patients living with type 2 diabetes with multiple risk factors for or established cardiovascular disease. "These data could help change the way we approach diabetes management; going beyond a singular focus on glucose control to help address the risk of heart failure in a diverse population of patients." The results of the DECLARE-TIMI 58 trial showed that people with type 2 diabetes and at risk of atherosclerotic cardiovascular disease had a 17% lower risk of hospitalisation for heart failure than those assigned to receive placebo. The trial showed no significant differences, between dapagliflozin and placebo, in the risks of major adverse cardiovascular events (MACE) such as heart disease, stroke from blood clots or death from cardiovascular disease.

    Continue reading...
    • Useful Useful x 1
  2. ickihun

    ickihun Type 2 · Master

    Likes Received:
    Trophy Points:
    Still not enough for me to suffer the constant thrush even with intense treatment.
    If they can solve the thrush side effect I'd be happy to take if needed in the future. Currently still reducing insulin need. I might not even need that next year. So diet and weight change is much more potent.
  • Meet the Community

    Find support, connect with others, ask questions and share your experiences with people with diabetes, their carers and family.

    Did you know: 7 out of 10 people improve their understanding of diabetes within 6 months of being a Diabetes Forum member. Get the Diabetes Forum App and stay connected on iOS and Android

    Grab the app!
  • Tweet with us

  • Like us on Facebook